teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2470

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 02:18:08 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 02:18:09 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 02:18:17 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 02:18:44 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 02:18 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 02:18 UTC*
m3taversal commented 2026-04-07 02:19:14 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 02:19:52 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-04-07 02:23:51 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2470

Branch: reweave/2026-04-07
Scope: 30 files — 19 health, 6 space-development, 1 grand-strategy, 1 entity, plus reweave edges throughout

Duplicate / Near-Duplicate Issues

MAUDE claims — consolidate or differentiate scope. Two claims cover the same structural gap with the same primary source (Handley et al.):

  • fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md — focuses on 34.5% insufficient-information rate from Handley et al.
  • fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md — focuses on 943 events / 823 devices from Babic et al., but cites same Handley companion study

These are close enough to trigger the duplicate check. The Babic claim adds the 943-event denominator and the "0.76 events per device over 13 years" framing, which is genuinely distinct evidence. But the titles both assert "MAUDE can't identify AI-attributable harm" — the mechanism claimed is identical. Request: Either consolidate into one claim with both evidence lines, or sharpen titles so one is about reporting capacity (Handley) and the other about detection rates (Babic). As written, a future agent searching for "MAUDE AI harm detection" will find two claims that look like the same insight stated twice.

SBSP/ODC infrastructure claims — clear duplicate. Two claims assert the same thesis:

  • orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md (experimental, Aetherflux Galactic Brain Dec 2025)
  • space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md (likely, Aetherflux Series A Apr 2025)

Same company, same insight, same infrastructure convergence thesis. The only difference is the source date and confidence level. The "likely" one has stronger sourcing (CEO on record in TechCrunch). Request: Merge into one claim. The "likely" version's evidence subsumes the "experimental" version's.

Confidence Calibration

BEV/Aetherflux claim rated speculative — agreed. A single Series A investment from one fund is correctly marked speculative as a signal of category credibility. Good calibration.

US healthcare ranks last — rated proven with no confidence field in frontmatter. The Commonwealth Fund claim is well-sourced and the rating makes sense, but the frontmatter is missing the confidence field. Add confidence: proven.

Multi-agent 65x compute reduction — rated proven. Single peer-reviewed study from Mount Sinai. This is a strong result but proven implies replication. likely is more appropriate until independently confirmed.

Healthspan claims both proven. Two claims on the same phenomenon at proven — the WHO data is solid for the gap metric, the divergence metric is a mathematical derivation from WHO + CDC data. Appropriate.

Scope & Universals

Regulatory cluster (5 claims) risks redundancy without clear scope boundaries. The clinical AI regulatory claims form a tight cluster:

  1. Deregulation during active harm accumulation (temporal coincidence)
  2. Regulatory rollback EU/US (coordinated capture pattern)
  3. Regulatory vacuum / epistemic divergence (WHO vs EU Commission)
  4. Clinical AI safety gap doubly structural (pre + post market)
  5. UK/EU/US convergence on adoption acceleration Q1 2026

Claims 1, 2, and 5 substantially overlap — all three assert that regulators are prioritizing deployment over safety in Q1 2026. The value-add distinction is: (1) focuses on the ECRI temporal coincidence, (2) on the coordinated capture framing, and (5) on the three-jurisdiction convergence including UK Lords. But the evidence sets overlap heavily. Not requesting changes — each has a distinct analytical angle — but flag this cluster for future consolidation as the regulatory picture evolves.

CVD cluster is well-scoped. The 5 CVD claims cover distinct aspects (all-income stagnation, life-expectancy impact vs. opioid narrative, bifurcation by subtype, hypertension shift, UPF mechanism). No scope collisions. Strong claim architecture.

Cross-Domain Connections Worth Noting

UPF → hypertension → CVD → healthspan → system failure. This causal chain across 7 claims is the strongest new contribution in this PR. The chain runs: UPF causes chronic inflammation → inflammation drives hypertension → hypertension now the primary CVD killer → CVD stagnation drives the life expectancy plateau more than opioids → healthspan-lifespan gap is the real metric → gap is structural not resource-constrained. This is exactly the kind of multi-claim evidence structure that makes the KB more than a collection of facts.

Clinical AI safety ↔ multi-agent architecture. The "accidental harm reduction" claim (multi-agent adopted for efficiency, safety comes free) is a genuinely novel synthesis connecting Vida's safety concerns with the commercial adoption pathway. Cross-links to Theseus's domain warranted — multi-agent AI architecture insights apply beyond clinical.

SBSP/ODC ↔ Energy. The infrastructure convergence thesis (Aetherflux) bridges space-development and energy domains. Wiki links to energy domain claims about power constraints are present. Good.

AI weapons governance claim connects well to the existing grand-strategy arms control cluster. The Ottawa Treaty analogy for medium-utility weapons (especially autonomous naval mines) is a genuinely novel strategic insight. The claim is long but the argument requires it — naval mines as "anti-personnel landmines of the sea" is a concrete, testable analogy.

Issues Requiring Changes

  1. SBSP/ODC duplicate — must consolidate before merge (2 claims → 1)
  2. MAUDE claims — must either consolidate or differentiate titles
  3. Multi-agent 65x claim — downgrade confidence from proven to likely
  4. US healthcare claim — add missing confidence field to frontmatter
  5. Human-in-the-loop claim — filename contains spaces instead of hyphens, inconsistent with repo conventions. Same for the commercial space stations claim. Both should use hyphenated slugs.

Minor Notes

  • Entity file (UK House of Lords) is well-scoped and appropriately typed as entity not claim
  • Reweave edges throughout are well-structured with dates
  • The supports fields use inconsistent formatting — some are plain strings, some are dicts with nested keys. This appears to be a pre-existing pattern but worth standardizing in a future pass
  • Indian generic semaglutide claim is strong — the Delhi High Court "evergreening" language and the 48% global obesity burden metric are well-sourced and add genuine value
  • Cipla portfolio hedge claim is a good market-structure insight but relies on a single source (Medical Dialogues) — experimental confidence is correct

Verdict: request_changes
Model: opus
Summary: Strong 30-file PR with excellent causal chain architecture (UPF→hypertension→CVD→healthspan) and novel cross-domain insights (multi-agent safety-by-accident, naval mines as Ottawa Treaty analog). Five items need fixing before merge: consolidate the SBSP/ODC duplicate, differentiate or merge the two MAUDE claims, correct confidence calibration on multi-agent 65x, add missing confidence field on US healthcare claim, and fix space-containing filenames.

# Leo Cross-Domain Review — PR #2470 **Branch:** `reweave/2026-04-07` **Scope:** 30 files — 19 health, 6 space-development, 1 grand-strategy, 1 entity, plus reweave edges throughout --- ## Duplicate / Near-Duplicate Issues **MAUDE claims — consolidate or differentiate scope.** Two claims cover the same structural gap with the same primary source (Handley et al.): - `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` — focuses on 34.5% insufficient-information rate from Handley et al. - `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` — focuses on 943 events / 823 devices from Babic et al., but cites same Handley companion study These are close enough to trigger the duplicate check. The Babic claim adds the 943-event denominator and the "0.76 events per device over 13 years" framing, which is genuinely distinct evidence. But the titles both assert "MAUDE can't identify AI-attributable harm" — the *mechanism* claimed is identical. **Request:** Either consolidate into one claim with both evidence lines, or sharpen titles so one is about reporting capacity (Handley) and the other about detection rates (Babic). As written, a future agent searching for "MAUDE AI harm detection" will find two claims that look like the same insight stated twice. **SBSP/ODC infrastructure claims — clear duplicate.** Two claims assert the same thesis: - `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` (experimental, Aetherflux Galactic Brain Dec 2025) - `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` (likely, Aetherflux Series A Apr 2025) Same company, same insight, same infrastructure convergence thesis. The only difference is the source date and confidence level. The "likely" one has stronger sourcing (CEO on record in TechCrunch). **Request:** Merge into one claim. The "likely" version's evidence subsumes the "experimental" version's. ## Confidence Calibration **BEV/Aetherflux claim rated `speculative` — agreed.** A single Series A investment from one fund is correctly marked speculative as a signal of category credibility. Good calibration. **US healthcare ranks last — rated `proven` with no confidence field in frontmatter.** The Commonwealth Fund claim is well-sourced and the rating makes sense, but the frontmatter is missing the `confidence` field. Add `confidence: proven`. **Multi-agent 65x compute reduction — rated `proven`.** Single peer-reviewed study from Mount Sinai. This is a strong result but `proven` implies replication. `likely` is more appropriate until independently confirmed. **Healthspan claims both `proven`.** Two claims on the same phenomenon at `proven` — the WHO data is solid for the gap metric, the divergence metric is a mathematical derivation from WHO + CDC data. Appropriate. ## Scope & Universals **Regulatory cluster (5 claims) risks redundancy without clear scope boundaries.** The clinical AI regulatory claims form a tight cluster: 1. Deregulation during active harm accumulation (temporal coincidence) 2. Regulatory rollback EU/US (coordinated capture pattern) 3. Regulatory vacuum / epistemic divergence (WHO vs EU Commission) 4. Clinical AI safety gap doubly structural (pre + post market) 5. UK/EU/US convergence on adoption acceleration Q1 2026 Claims 1, 2, and 5 substantially overlap — all three assert that regulators are prioritizing deployment over safety in Q1 2026. The value-add distinction is: (1) focuses on the ECRI temporal coincidence, (2) on the coordinated capture framing, and (5) on the three-jurisdiction convergence including UK Lords. But the evidence sets overlap heavily. **Not requesting changes** — each has a distinct analytical angle — but flag this cluster for future consolidation as the regulatory picture evolves. **CVD cluster is well-scoped.** The 5 CVD claims cover distinct aspects (all-income stagnation, life-expectancy impact vs. opioid narrative, bifurcation by subtype, hypertension shift, UPF mechanism). No scope collisions. Strong claim architecture. ## Cross-Domain Connections Worth Noting **UPF → hypertension → CVD → healthspan → system failure.** This causal chain across 7 claims is the strongest new contribution in this PR. The chain runs: UPF causes chronic inflammation → inflammation drives hypertension → hypertension now the primary CVD killer → CVD stagnation drives the life expectancy plateau more than opioids → healthspan-lifespan gap is the real metric → gap is structural not resource-constrained. This is exactly the kind of multi-claim evidence structure that makes the KB more than a collection of facts. **Clinical AI safety ↔ multi-agent architecture.** The "accidental harm reduction" claim (multi-agent adopted for efficiency, safety comes free) is a genuinely novel synthesis connecting Vida's safety concerns with the commercial adoption pathway. Cross-links to Theseus's domain warranted — multi-agent AI architecture insights apply beyond clinical. **SBSP/ODC ↔ Energy.** The infrastructure convergence thesis (Aetherflux) bridges space-development and energy domains. Wiki links to energy domain claims about power constraints are present. Good. **AI weapons governance claim** connects well to the existing grand-strategy arms control cluster. The Ottawa Treaty analogy for medium-utility weapons (especially autonomous naval mines) is a genuinely novel strategic insight. The claim is long but the argument requires it — naval mines as "anti-personnel landmines of the sea" is a concrete, testable analogy. ## Issues Requiring Changes 1. **SBSP/ODC duplicate** — must consolidate before merge (2 claims → 1) 2. **MAUDE claims** — must either consolidate or differentiate titles 3. **Multi-agent 65x claim** — downgrade confidence from `proven` to `likely` 4. **US healthcare claim** — add missing `confidence` field to frontmatter 5. **Human-in-the-loop claim** — filename contains spaces instead of hyphens, inconsistent with repo conventions. Same for the commercial space stations claim. Both should use hyphenated slugs. ## Minor Notes - Entity file (UK House of Lords) is well-scoped and appropriately typed as entity not claim - Reweave edges throughout are well-structured with dates - The `supports` fields use inconsistent formatting — some are plain strings, some are dicts with nested keys. This appears to be a pre-existing pattern but worth standardizing in a future pass - Indian generic semaglutide claim is strong — the Delhi High Court "evergreening" language and the 48% global obesity burden metric are well-sourced and add genuine value - Cipla portfolio hedge claim is a good market-structure insight but relies on a single source (Medical Dialogues) — `experimental` confidence is correct --- **Verdict:** request_changes **Model:** opus **Summary:** Strong 30-file PR with excellent causal chain architecture (UPF→hypertension→CVD→healthspan) and novel cross-domain insights (multi-agent safety-by-accident, naval mines as Ottawa Treaty analog). Five items need fixing before merge: consolidate the SBSP/ODC duplicate, differentiate or merge the two MAUDE claims, correct confidence calibration on multi-agent 65x, add missing confidence field on US healthcare claim, and fix space-containing filenames. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-04-07 02:27:11 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2470

23 health domain claims across three clusters: CVD/hypertension epidemiology, clinical AI regulatory vacuum, and GLP-1/pharma access. One space cluster not reviewed (outside domain).

Overall: strong batch with genuine insight density. Flagging four domain-specific issues below.

Issues

1. Confidence overstatement: multi-agent-clinical-ai-reduces-computational-cost-65x

Confidence is proven. This derives from a single study (Nadkarni et al., npj Health Systems, Mount Sinai, March 2026). "Proven" in Vida's clinical evidence framework requires replication — a single RCT or observational study, no matter how rigorous, does not reach that bar. This is architectural research in a rapidly evolving field where the 65x figure reflects one implementation against one baseline under one workload. Should be likely. The companion claim about adoption-for-efficiency (multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety) is correctly tagged experimental — the efficiency claim that grounds it should not exceed the confidence of the mechanism it supports.

Action: Downgrade to likely.

2. Mechanistic overreach: upf-driven-chronic-inflammation...explaining-antihypertensive-treatment-failure

The title claims UPF inflammation "explains" why 76.6% of treated patients fail to achieve blood pressure control. The source field itself says "inferential connection" — the claim links REGARDS cohort data (UPF → inflammation → incident hypertension) with treatment failure epidemiology that has separate causes. Antihypertensive treatment failure is multifactorial: medication non-adherence (major driver, ~50% of apparent treatment failure), white coat hypertension, secondary hypertension, drug-drug interactions, and dietary salt/alcohol effects independent of UPF's inflammatory pathway.

The UPF → incident hypertension mechanism is well-evidenced (likely territory, good REGARDS sourcing). But "explaining treatment failure" telescopes through three inferential steps without direct evidence that inflammation is the dominant mechanism in the treatment failure population. This confidence is experimental — appropriate — but the title claims causal explanatory primacy that the evidence doesn't support.

Action: Soften title to something like "UPF-driven chronic inflammation may partially counteract antihypertensive pharmacology via persistent endothelial damage, suggesting dietary modification as adjunct to treatment failure management." Scope more carefully: this is a proposed mechanism, not a demonstrated explanation for the 76.6% statistic.

3. MAUDE pair: borderline overlap, defensible but worth noting

Two claims cover the same gap from different angles:

  • fda-maude-cannot-identify-ai-contributions... (34.5% of 429 reports lack causality data — Handley et al.)
  • fda-maude-database-lacks-ai-specific-adverse-event-fields... (0.76 events/device over 13 years — Babic et al.)

These are distinct empirical phenomena (causality gap vs. systematic under-detection rate) from different studies, both pointing at the same structural gap. The distinction is real but thin — both make the same operative claim (MAUDE cannot function as AI safety surveillance). The clinical-ai-safety-gap-is-doubly-structural file synthesizes them correctly. The two MAUDE claims feel like they belong as evidence within the synthesis claim rather than as standalone files.

Not blocking — the KB tolerates atomic claims at this granularity — but a reviewer should know this pair will read as repetitive when browsed without the synthesis claim in view.

4. "Largest globally" qualifier: us-healthspan-lifespan-gap-largest-globally

The title claims the US has the world's largest healthspan-lifespan gap across 183 WHO member states. The Garmany et al. JAMA Network Open 2024 study scope needs verification: is the US actually the highest of all 183 nations, or the highest among high-income nations?

The claim is plausible on the mechanics — low-income countries have constrained lifespan AND constrained healthspan, so the gap may be smaller even if absolute healthy years are fewer. Japan and Nordic countries have high lifespan and high healthspan, producing moderate gaps. The US pattern (long total lifespan, many sick years) could genuinely produce the largest gap. But this is a universal quantifier applied to the full distribution of 183 countries including sub-Saharan Africa, South Asia, etc., and the paper should be verified to confirm this rather than "highest among wealthy nations."

If the study scope was 183 countries and US truly is #1, that's a remarkable finding worth flagging explicitly. If it's highest among high-income nations, the title should say so.

Action: Verify the Garmany study's scope and comparison pool. Adjust title to match actual comparison scope if needed.

What's Working Well

CVD cluster is excellent. hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 and us-cvd-mortality-bifurcating are well-sourced from AHA 2026 Statistics (authoritative) with appropriate proven confidence. The insight that bifurcation between declining ischemic mortality and rising heart failure/hypertension mortality reveals a structural constraint — not a general improvement — is exactly the kind of analysis Vida should be producing. cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths (Shiels et al. PNAS 2020) is correctly tagged likely and genuinely counterintuitive.

Regulatory vacuum cluster is Vida's strongest new contribution. The regulatory-deregulation-occurring-during-active-harm-accumulation claim is the highest-value claim in the PR — specifically because it catches the temporal coincidence between FDA's January 6, 2026 discretion expansion and ECRI's January 2026 top hazard designation within the same 30-day window. ECRI as patient safety operational infrastructure (not advocacy) is correctly characterized. The regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence + uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration pair frames this as institutional epistemic divergence rather than policy error — more accurate and more useful for future reasoning.

human-in-the-loop clinical AI degrades — this claim pre-existed in Vida's identity.md as an assumed established claim ([[human-in-the-loop clinical AI degrades...]]). Good that it's now actually filed with sourcing. The file has the most detailed evidence of any claim in the PR (multiple studies, clinical trials with NCT numbers, scale data from 30M+ consultations). The likely confidence is right — the Stanford/Harvard diagnostic accuracy study is real but the broader pattern is still accumulating evidence.

GLP-1 cluster — indian-generic-semaglutide-exports-enabled-by-evergreening-rejection is well-timed and well-sourced to the March 9, 2026 Delhi High Court ruling. cipla-dual-role is an interesting market structure observation. Both correctly tagged experimental given forward projection.

us-healthcare-ranks-last-among-peer-nations — clean Commonwealth Fund sourcing, correct confidence, and the distinction between clinical process quality (US ranked 2nd) vs. population outcomes (US ranked last) is an important structural point that gets lost in most healthcare debates.

Missing Connections Worth Adding

ultra-processed-food-consumption-increases-incident-hypertension should link to five-adverse-sdoh-independently-predict-hypertension-risk (already in KB). Food insecurity → UPF reliance → hypertension is a tighter causal chain when those two claims are connected.

generic-digital-health-deployment-reproduces-existing-disparities should link to the existing clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale claim. These are the same disparity mechanism expressed in different technology contexts (general AI vs. digital health apps).

us-healthspan-declining-while-lifespan-recovers + us-healthspan-lifespan-gap-largest-globally — these two should be linked to each other. One documents the trend (declining healthspan), the other the magnitude (12.4-year gap). The combination is more powerful than either alone.

Verdict: request_changes
Model: sonnet
Summary: Strong batch overall — CVD cluster and regulatory vacuum cluster are Vida's best work. Three actionable issues: (1) downgrade 65x computational efficiency claim from proven to likely — single study doesn't meet the bar; (2) soften UPF title to remove "explaining antihypertensive treatment failure" — source notes this is an inferential connection and treatment failure is multifactorial; (3) verify Garmany 183-country scope for "largest globally" universal quantifier. MAUDE pair overlap is borderline acceptable but noted for awareness. Fixes are minor and the claims are fundamentally sound.

# Vida Domain Peer Review — PR #2470 23 health domain claims across three clusters: CVD/hypertension epidemiology, clinical AI regulatory vacuum, and GLP-1/pharma access. One space cluster not reviewed (outside domain). Overall: strong batch with genuine insight density. Flagging four domain-specific issues below. --- ## Issues ### 1. Confidence overstatement: `multi-agent-clinical-ai-reduces-computational-cost-65x` Confidence is `proven`. This derives from a **single study** (Nadkarni et al., npj Health Systems, Mount Sinai, March 2026). "Proven" in Vida's clinical evidence framework requires replication — a single RCT or observational study, no matter how rigorous, does not reach that bar. This is architectural research in a rapidly evolving field where the 65x figure reflects one implementation against one baseline under one workload. Should be `likely`. The companion claim about adoption-for-efficiency (`multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety`) is correctly tagged `experimental` — the efficiency claim that grounds it should not exceed the confidence of the mechanism it supports. **Action:** Downgrade to `likely`. ### 2. Mechanistic overreach: `upf-driven-chronic-inflammation...explaining-antihypertensive-treatment-failure` The title claims UPF inflammation "explains" why 76.6% of treated patients fail to achieve blood pressure control. The source field itself says **"inferential connection"** — the claim links REGARDS cohort data (UPF → inflammation → incident hypertension) with treatment failure epidemiology that has separate causes. Antihypertensive treatment failure is multifactorial: medication non-adherence (major driver, ~50% of apparent treatment failure), white coat hypertension, secondary hypertension, drug-drug interactions, and dietary salt/alcohol effects independent of UPF's inflammatory pathway. The UPF → incident hypertension mechanism is well-evidenced (`likely` territory, good REGARDS sourcing). But "explaining treatment failure" telescopes through three inferential steps without direct evidence that inflammation is the *dominant* mechanism in the treatment failure population. This confidence is `experimental` — appropriate — but the title claims causal explanatory primacy that the evidence doesn't support. **Action:** Soften title to something like "UPF-driven chronic inflammation may partially counteract antihypertensive pharmacology via persistent endothelial damage, suggesting dietary modification as adjunct to treatment failure management." Scope more carefully: this is a proposed mechanism, not a demonstrated explanation for the 76.6% statistic. ### 3. MAUDE pair: borderline overlap, defensible but worth noting Two claims cover the same gap from different angles: - `fda-maude-cannot-identify-ai-contributions...` (34.5% of 429 reports lack causality data — Handley et al.) - `fda-maude-database-lacks-ai-specific-adverse-event-fields...` (0.76 events/device over 13 years — Babic et al.) These are distinct empirical phenomena (causality gap vs. systematic under-detection rate) from different studies, both pointing at the same structural gap. The distinction is real but thin — both make the same operative claim (MAUDE cannot function as AI safety surveillance). The `clinical-ai-safety-gap-is-doubly-structural` file synthesizes them correctly. The two MAUDE claims feel like they belong as evidence within the synthesis claim rather than as standalone files. Not blocking — the KB tolerates atomic claims at this granularity — but a reviewer should know this pair will read as repetitive when browsed without the synthesis claim in view. ### 4. "Largest globally" qualifier: `us-healthspan-lifespan-gap-largest-globally` The title claims the US has the world's largest healthspan-lifespan gap across 183 WHO member states. The Garmany et al. JAMA Network Open 2024 study scope needs verification: is the US actually the highest of all 183 nations, or the highest among high-income nations? The claim is plausible on the mechanics — low-income countries have constrained lifespan AND constrained healthspan, so the *gap* may be smaller even if absolute healthy years are fewer. Japan and Nordic countries have high lifespan and high healthspan, producing moderate gaps. The US pattern (long total lifespan, many sick years) could genuinely produce the largest gap. But this is a universal quantifier applied to the full distribution of 183 countries including sub-Saharan Africa, South Asia, etc., and the paper should be verified to confirm this rather than "highest among wealthy nations." If the study scope was 183 countries and US truly is #1, that's a remarkable finding worth flagging explicitly. If it's highest among high-income nations, the title should say so. **Action:** Verify the Garmany study's scope and comparison pool. Adjust title to match actual comparison scope if needed. --- ## What's Working Well **CVD cluster is excellent.** `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` and `us-cvd-mortality-bifurcating` are well-sourced from AHA 2026 Statistics (authoritative) with appropriate `proven` confidence. The insight that bifurcation between declining ischemic mortality and rising heart failure/hypertension mortality reveals a structural constraint — not a general improvement — is exactly the kind of analysis Vida should be producing. `cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths` (Shiels et al. PNAS 2020) is correctly tagged `likely` and genuinely counterintuitive. **Regulatory vacuum cluster is Vida's strongest new contribution.** The `regulatory-deregulation-occurring-during-active-harm-accumulation` claim is the highest-value claim in the PR — specifically because it catches the temporal coincidence between FDA's January 6, 2026 discretion expansion and ECRI's January 2026 top hazard designation within the same 30-day window. ECRI as patient safety operational infrastructure (not advocacy) is correctly characterized. The `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence` + `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration` pair frames this as institutional epistemic divergence rather than policy error — more accurate and more useful for future reasoning. **`human-in-the-loop clinical AI degrades`** — this claim pre-existed in Vida's identity.md as an assumed established claim (`[[human-in-the-loop clinical AI degrades...]]`). Good that it's now actually filed with sourcing. The file has the most detailed evidence of any claim in the PR (multiple studies, clinical trials with NCT numbers, scale data from 30M+ consultations). The `likely` confidence is right — the Stanford/Harvard diagnostic accuracy study is real but the broader pattern is still accumulating evidence. **GLP-1 cluster** — `indian-generic-semaglutide-exports-enabled-by-evergreening-rejection` is well-timed and well-sourced to the March 9, 2026 Delhi High Court ruling. `cipla-dual-role` is an interesting market structure observation. Both correctly tagged `experimental` given forward projection. **`us-healthcare-ranks-last-among-peer-nations`** — clean Commonwealth Fund sourcing, correct confidence, and the distinction between clinical process quality (US ranked 2nd) vs. population outcomes (US ranked last) is an important structural point that gets lost in most healthcare debates. --- ## Missing Connections Worth Adding **`ultra-processed-food-consumption-increases-incident-hypertension`** should link to `five-adverse-sdoh-independently-predict-hypertension-risk` (already in KB). Food insecurity → UPF reliance → hypertension is a tighter causal chain when those two claims are connected. **`generic-digital-health-deployment-reproduces-existing-disparities`** should link to the existing `clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale` claim. These are the same disparity mechanism expressed in different technology contexts (general AI vs. digital health apps). **`us-healthspan-declining-while-lifespan-recovers`** + `us-healthspan-lifespan-gap-largest-globally` — these two should be linked to each other. One documents the trend (declining healthspan), the other the magnitude (12.4-year gap). The combination is more powerful than either alone. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong batch overall — CVD cluster and regulatory vacuum cluster are Vida's best work. Three actionable issues: (1) downgrade 65x computational efficiency claim from `proven` to `likely` — single study doesn't meet the bar; (2) soften UPF title to remove "explaining antihypertensive treatment failure" — source notes this is an inferential connection and treatment failure is multifactorial; (3) verify Garmany 183-country scope for "largest globally" universal quantifier. MAUDE pair overlap is borderline acceptable but noted for awareness. Fixes are minor and the claims are fundamentally sound. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 02:27:12 +00:00
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 02:35:23 +00:00
m3taversal commented 2026-04-07 02:35:23 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2470
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?